

Contents

xv Preface to the Third, Revised and Expanded Edition

Wiersinga, W.M. (Amsterdam); Kahaly, G.J. (Mainz)

xvi Preface to the Second, Revised Edition

Wiersinga, W.M. (Amsterdam); Kahaly, G.J. (Mainz)

xvi Preface to the First Edition

Wiersinga, W.M. (Amsterdam); Kahaly, G.J. (Mainz)

Diagnosis and Pathogenesis

1 Clinical Manifestations

Dickinson, A.J. (Newcastle upon Tyne); Hintschich, C. (Munich)

- 1 What Are the Common Signs and Symptoms of Early Graves' Orbitopathy?
- 1 What Are Other Signs and Symptoms of Graves' Orbitopathy?
- 3 What Signs Should Question the Diagnosis of Graves' Orbitopathy?
- 3 Are There Racial Differences in How Graves' Orbitopathy Manifests?
- 4 Is the Presentation of Graves' Orbitopathy Different in Older Compared to Younger Patients?
- 4 Why Can the Clinical Presentation of Graves' Orbitopathy Be So Variable?
- 5 Can You Give Me a Short Mechanistic Explanation for All These Clinical Manifestations?
- 6 What Do the Terms "Activity" and "Severity" Denote?
- 7 Why Is It Important to Distinguish Activity and Severity when Evaluating Patients?
- 7 What Signs and Symptoms Are Valuable for Assessing Activity?
- 7 How Are These Signs Assessed?
- 10 How Reproducible Are These Assessments?
- 11 What Value Does the "Clinical Activity Score" Have?
- 11 Do Patients without Signs of Activity Ever Have Active Disease?
- 12 What Should I Do if I Am Not Sure whether the Disease Is Active?
- 12 Are There Any Other Ways to Evaluate Activity other than Clinical Examination?
- 13 When Should These Other Methods for Assessing Activity Be Used in Routine Clinical Practice?
- 14 What Signs Are Helpful for Assessing Severity?
- 14 What Value Does the Mnemonic "NOSPECS" Have?
- 14 How Are Signs of Severity Assessed?
- 18 How Reproducible Are These Assessments?
- 19 How Is Severity Best Classified?
- 19 How Do You Decide whether a Patient Has Dysthyroid Optic Neuropathy?
- 21 Can Dysthyroid Optic Neuropathy Ever Be Present with Normal Vision?
- 21 Are Some Patients at Particular Risk?
- 21 What Other Assessments Are Useful in Evaluating Possible Dysthyroid Optic Neuropathy?
- 22 Should These Tests Be Performed in All Patients at Every Assessment?
- 22 Are There Any Other Assessment Systems in Common Use?
- 23 References

26 Orbit-Thyroid Relationship

Marinò, M. (Pisa)

- 26 Should This Condition Always Be Called Graves' Orbitopathy?
- 26 Is Graves' Orbitopathy Exclusively Occurring in Patients with Graves' Hyperthyroidism?
- 28 Do All Patients with Graves' Hyperthyroidism Have Graves' Orbitopathy?
- 28 Are There Any Relationships between Hyperthyroidism, Hypothyroidism, and Graves' Orbitopathy?
- 29 Is Graves' Orbitopathy Related to Thyroid Autoimmunity?
- 29 Are There Other Extrathyroidal Manifestations of Graves' Disease apart from Graves' Orbitopathy?
- 31 References

33 Epidemiology

Burlacu, M.-C.; Daumerie, C. (Brussels)

- 33 What Is the Estimated Incidence and Prevalence of Graves' Orbitopathy?
- 34 Has the Occurrence of Graves' Orbitopathy Changed over the Last Few Decades?
- 35 Is the Age and Sex Distribution of Graves' Orbitopathy Similar to That of Graves' Hyperthyroidism?
- 36 Are There Ethnic Differences?
- 36 What Are the Risk Factors for the Occurrence of Graves' Orbitopathy?
- 37 Can Particular Drugs Trigger or Modify Graves' Orbitopathy and Its Course?
- 38 Is Tobacco Bad for Graves' Orbitopathy?
- 38 Has Nutrition an Effect on Graves' Orbitopathy?
- 38 Does Total Thyroidectomy for Other Diseases than Graves' Disease Preclude the Development of Graves' Orbitopathy?
- 39 References

41 Pathogenesis

Salvi, M. (Milan); Berchner-Pfannschmidt, U. (Essen); Ludgate, M. (Cardiff)

- 41 What Are the Pathological Changes in Orbital Tissue in Graves' Orbitopathy?
- 43 How Do the Pathological Changes Give Rise to the Clinical Manifestations?
- 44 What Triggers Graves' Orbitopathy?
- 45 Is Graves' Orbitopathy Triggered by an Autoimmune Phenomenon? If So, What Is the Nature of the Autoantigen?
- 47 Why Is the Orbit Special and a Target for Thyroid Autoimmunity?
- 48 What Kind of Immune Reactions Take Place within the Orbit?
- 50 Does Thyroid-Stimulating Hormone Receptor Activation and/or Autoreactivity to Thyroid-Stimulating Hormone Receptor Play a Role in the Onset or Development of Graves' Orbitopathy?
- 52 Is There a Familial Predisposition or a Specific Genetic Background for Graves' Orbitopathy?
- 53 How Do Environmental Factors Increase the Risk and Severity of Graves' Orbitopathy?
- 54 How May These Observations and Current Understanding Lead to More Effective Treatment of Graves' Orbitopathy?
- 56 References

61 Orbital Imaging

Pitz, S.; Müller-Forell, W. (Mainz)

- 61 Is Orbital Imaging Always Necessary?
- 61 What Are the Relative Benefits of Orbital CT and MRI?
- 65 What Is Apical Crowding?
- 68 What Is the Place of Orbital Ultrasound?
- 70 What Lessons Can We Learn from Orbital Octreoscan?
- 70 What Other Imaging Techniques May Be Useful?
- 71 References

74 Diagnosis and Differential Diagnosis of Graves' Orbitopathy

Konuk, O. (Ankara); Anagnostis, P. (Thessaloniki)

- 74 Can You Give an Overall Scheme for the Diagnosis of Graves' Orbitopathy?
- 75 Which Clinical Findings Are Helpful in Making a Diagnosis of Graves' Orbitopathy?
- 81 Can One Make a Diagnosis of Graves' Orbitopathy Based on Medical History and Clinical Picture Alone?
- 82 Do We Always Need to Order Thyroid Autoantibody and Thyroid Function Tests?
- 83 Which Imaging Technique Is Best to Make a Diagnosis of Graves' Orbitopathy, and Is Imaging Always Requested?
- 84 Which Are the Most Frequent Conditions Mimicking Graves' Orbitopathy?
- 91 References

93 Natural History

Mamoojee, Y.; Pearce, S.H.S. (Newcastle upon Tyne)

- 93 Does Graves' Orbitopathy Occur at the Same Time as Hyperthyroidism?
- 94 Does Restoring Euthyroidism Lead to Improvement in Graves' Orbitopathy?
- 95 What Effect May Hypothyroidism Have?
- 95 What Is the Typical Course of the Disease?
- 96 What Happens to Orbital Fat during the Course of the Disease?
- 97 What Is the Difference between Activity and Severity?
- 99 How Do You Determine Which Phase of the Disease the Patient Is Displaying?
- 99 How Does the Phase of the Disease Influence the Choice of Treatment?
- 100 Will Graves' Orbitopathy Eventually Burn Itself Out?
- 100 Will the Orbital Changes Return to Normal when the Condition Eventually Resolves?
- 100 How Long Is It Likely to Take before the Disease Becomes Inactive?
- 101 Once the Condition Has Become Inactive (whether Treated or Untreated), Is It Likely to Flare Up Again?
- 101 Are There Any Other Factors, Additional to Thyroid Status, That May Influence the Course of the Disease?
- 102 References

Management

105 General Management Plan for Graves' Orbitopathy

Bartalena, L. (Varese)

- 105 Is There General Agreement among Specialists on How to Manage Graves' Orbitopathy?
- 105 What Are the Priorities when Faced with a New Presentation of Graves' Orbitopathy?
- 107 Should the Patient Be Informed about Risk Factors Affecting the Course of Graves' Orbitopathy?
- 108 What Is the Evidence about the Role of Smoking on the Course of Graves' Orbitopathy?
- 109 Does Thyroid Status Affect Graves' Orbitopathy?
- 109 Are There Simple Measures That Can Help the Eyes?
- 110 Is Early Referral to Specialized Centres Important?
- 111 Can You Provide the Patient with an Overall Management Scheme?
- 111 References

113 Combined Thyroid-Eye Clinics

Törüner, F.B.; Konuk, O.; Ayvaz, G. (Ankara)

- 113 What Are Combined Thyroid-Eye Clinics?
- 115 Why Is a Multidisciplinary Approach Recommended?

- 115 Can Patient Support Groups Be Helpful?
- 117 I Have Heard of a Fast-Track Clinic for Graves' Orbitopathy Patients: What Is That?
- 117 What Can I Expect when Starting a Combined Thyroid-Eye Clinic?
- 117 References
- 119 Thyroid Treatment**
Hegedüs, L.; Brix, T.H. (Odense)
- 120 Do the Eyes Care How Euthyroidism Is Obtained and Maintained?
- 123 Are There Criteria for Preferring One of the Treatment Options for Hyperthyroidism over the Others in Graves' Orbitopathy?
- 124 Can Risk Factors Which Predict Appearance or Worsening of Graves' Orbitopathy after Radioiodine Be Identified?
- 125 Should the Presence of Graves' Orbitopathy Restrict Our Use of Radioiodine Therapy?
- 126 Does Avoiding Transient Hypothyroidism following Radioiodine Therapy Affect the Course of Graves' Orbitopathy?
- 127 What Is the Role of Total Thyroid Ablation in the Management of Hyperthyroidism in Graves' Orbitopathy?
- 128 Conclusions
- 128 References
- 131 Management of Mild Graves' Orbitopathy**
Mancocci, C.; Rocchi, R. (Pisa)
- 131 Which Parameters Should Be Taken into Account to Define a Clinically Evident Graves' Orbitopathy as Mild?
- 132 Are Mild Forms Likely to Progress to More Severe Graves' Orbitopathy?
- 133 Is a "Wait-and-See" Policy Justified in Patients with Mild Graves' Orbitopathy?
- 134 Are Low-Dosage Oral Steroids Advisable or Is Orbital Radiotherapy Preferable?
- 135 What Is the Rationale for Antioxidant Therapy like Selenium in Graves' Orbitopathy?
- 138 References
- 140 Management of Moderately Severe Graves' Orbitopathy**
Kahaly, G.J. (Mainz)
- 140 How Is Moderately Severe Graves' Orbitopathy Defined?
- 140 Is Immunosuppression Indicated in Moderately Severe Graves' Orbitopathy?
- 141 What Are the Cellular and Molecular Mechanisms of Steroid Anti-Inflammation and Immunosuppression?
- 145 What Are the Results of Randomized Trials with Steroids?
- 155 What Are the Results of Randomized Trials Using Orbital Radiotherapy?
- 159 Do You Favour Combined Steroid/Radiotherapy?
- 160 What Are the Results of Randomized Trials Using Non-Steroid Immunosuppressants?
- 165 What Are the Results of Randomized Trials Using Somatostatin Analogues?
- 167 How Should a Diabetic or Hypertensive Patient with Moderately Severe Graves' Orbitopathy Be Treated?
- 168 What Should You Do if Steroids Fail?
- 168 What Is the Optimal Thyroid Treatment in Patients with Graves' Hyperthyroidism and Moderately Severe Active Graves' Orbitopathy?
- 169 What Are the Actual Evidence-Based Therapeutic Recommendations for Patients with Moderately Severe Graves' Orbitopathy?
- 169 What Were the Recommendations of the EUGOGO Consensus Statement for the Management of Moderately Severe Graves' Orbitopathy?

170	What Do the ETA/EUGOGO Guidelines for the Management of Graves' Orbitopathy Recommend?	217
171	Acknowledgements	217
171	References	217
177	Novel Immunomodulatory Treatment Modalities	223
	Lane, L.C.; Perros, P.; Pearce, S.H.S. (Newcastle upon Tyne)	224
177	Why Look for New Immunomodulatory Treatments?	225
177	What Are the Targets for Potential Novel Therapies?	226
179	Rituximab	226
184	What Are the Most Likely Targets for Therapeutic Intervention?	227
189	Should Clinicians Be Cautious about Trying Novel Immunomodulators?	227
190	References	227
193	Management of Very Severe Graves' Orbitopathy: Dysthyroid Optic Neuropathy and Corneal Breakdown	230
	Boschi, A. (Brussels); Currò, N. (Milan)	230
193	How Do You Define Dysthyroid Optic Neuropathy? What Is the Causative Mechanism?	230
194	Are There Specific Risk Factors for Dysthyroid Optic Neuropathy?	231
195	Which Symptoms Should Alert Me for Dysthyroid Optic Neuropathy?	231
196	What Are the Ophthalmological Signs of Dysthyroid Optic Neuropathy?	231
196	Are Additional Investigations Helpful?	231
197	How Fast Can Dysthyroid Optic Neuropathy Progress? Is Urgent Treatment Necessary?	231
197	What Is the Evidence Base for the Treatment of Dysthyroid Optic Neuropathy?	231
198	Are Predictive Factors for Response to Steroid Treatment in Dysthyroid Optic Neuropathy Patients Well Defined?	231
199	What Is the Role of Surgery in Dysthyroid Optic Neuropathy?	231
199	How Many Patients Become Blind due to Dysthyroid Optic Neuropathy?	231
199	How Can I Recognize Corneal Breakdown?	231
200	What Is the Recommended Treatment of Corneal Breakdown?	231
200	References	231
202	Local Treatment Modalities	247
	Boboridis, K.; Anagnostis, P. (Thessaloniki)	247
202	Is Graves' Orbitopathy Related to Ocular Surface Pathology?	247
202	When and How Should We Support the Ocular Surface?	247
204	Can Local Measures Address Eyelid Retraction?	247
204	Can Local Measures Reduce Orbital Inflammation in Graves' Orbitopathy?	247
205	Can Local Measures Improve the Visual Disturbance and Diplopia?	247
205	References	247
207	Rehabilitative Surgery	256
	Baldeschi, L. (Brussels)	256
207	Why Is This Chapter Called Rehabilitative Surgery and Not Cosmetic Surgery?	257
208	What Are the Steps and Timing of Rehabilitative Surgery?	257
209	How Should Patients Be Selected for Rehabilitative Surgery?	257
210	References	257

211 Orbital Decompression

Baldeschi, L. (Brussels); Morris, D.S. (Cardiff)

211 What Is Orbital Decompression?

211 What Are the Aims of Orbital Decompression?

215 What Are the Different Types of Orbital Decompression?

223 What Are the Possible Complications of Orbital Decompression?

224 Can Complications Be Predicted or Prevented?

225 Are Technical Developments in Decompression Surgery and Other Surgical Rehabilitative Procedures for Graves' Orbitopathy to Be Expected?

226 Are Conceptual Developments in Decompression Surgery and Other Surgical Rehabilitative Procedures for Graves' Orbitopathy to Be Expected?

227 References

230 Eye Muscle Surgery

Nardi, M. (Pisa); Eckstein, A. (Essen)

230 What Are the Reasons for Impairment of Ocular Motility in Graves' Orbitopathy?

230 Which Muscles Are Involved?

231 How Does Decompression Influence Ocular Motility?

232 How Do You Identify the Affected Muscles?

234 How Can You Avoid Diagnostic Errors in Complex Cases?

236 What Is the Optimal Pretreatment before You Start Eye Muscle Surgery?

236 When Is the Right Time for Surgery?

236 How Do You Deal with Diplopia until Surgery Is Possible?

237 How Can You Evaluate the Need for Surgery?

238 The Surgical Plan: What Procedures Are Recommended?

241 What Are the Possible Complications of Surgery and How Can I Avoid or Manage Them?

243 What Can You Realistically Expect from Surgery?

243 How Can Success of Surgery Be Measured?

244 How Should You Advise the Patient?

244 References

247 Eyelid Surgery

Clarke, L. (Newcastle upon Tyne); Eckstein, A. (Essen)

247 What Are the Indications for Eyelid Surgery in Patients with Graves' Orbitopathy?

248 Is Botulinum Toxin Useful?

249 Is Surgical Intervention Indicated in Corneal Ulceration Secondary to Exposure Keratopathy?

250 Does Orbital Decompression Have Any Effect on Lid Retraction?

250 Does Squint Surgery Influence the Lid Configuration?

251 Can Decompression Be Combined with Lid Lengthening?

252 What Surgical Procedures Are Available for Correction of Upper Lid Retraction?

254 Are There Complications?

254 What Surgical Procedures Are Available for Correction of Lower Lid Retraction?

255 Should This Be Combined with Horizontal Lid Tightening?

256 Which Materials Are Suitable for Use as Spacers? Should the Use of Allogeneic Grafts Be Avoided?

257 Are There Complications?

257 What about Upper Lid Debulking and Upper and Lower Lid Blepharoplasty?

257 Does Lid Surgery Improve the Quality of Life of the Patients?

257 How Can the Effect of Lid Surgery Be Quantified?

258 References

260 Quality of Life

Wiersinga, W.M. (Amsterdam)

- 260 What Is Quality of Life?
- 260 What Is the Usefulness of Quality of Life Measurements?
- 262 What Is Known about General Health-Related Quality of Life in Graves' Orbitopathy?
- 263 Is There a Graves' Orbitopathy-Specific Quality of Life Questionnaire?
- 265 What Are the Results of the GO-QoL?
- 265 Can You Explain Response Shift in Quality of Life?
- 266 Can GO-QoL Be Used as a Separate Outcome Measurement in Graves' Orbitopathy?
- 267 What Is the Experience with GO-QoL as Outcome Measurement in the Literature?
- 268 Are There Other Disease-Specific Quality of Life Questionnaires for Graves' Orbitopathy?
- 270 Are There Qualitative Studies on Quality of Life in Graves' Orbitopathy?
- 270 Is Quality of Life Fully Restored after Treatment of Graves' Orbitopathy?
- 271 What Can I Conclude and Should I Apply the GO-QoL in My Own Practice?
- 272 References

275 Socioeconomic Impact

Kahaly, G.J. (Mainz)

- 275 Is There an Actual Cost Estimation of Thyroid Disorders in Germany and/or Europe?
- 276 Does Graves' Orbitopathy Lead to Occupational Disability?
- 276 How Were Data Obtained on Occupational Disability and Impaired Earning Capacity in Graves' Orbitopathy?
- 277 What Are the Findings of the Performed Prospective Study?
- 279 How Should We Interpret the Data Obtained on Occupational Disability and Impaired Earning Capacity in Patients with Graves' Orbitopathy?
- 279 What Are the Relevant Implications for the Daily Clinical Practice?
- 280 Do We Have Data on the Public Health Relevance of Graves' Orbitopathy?
- 283 References

285 The Patient's View

von Arx, G. (Olten); Ayvaz, G. (Ankara)

- 285 Due to the Changes of My Eyes and Skin I Have Not Only "Lost My Face"! Where Can I Get Support and Help?
- 286 Will the Treatment for the Thyroid Make the Eyes Better or Worse?
- 286 Can Graves' Orbitopathy Be Prevented?
- 287 Will My Eyes Always Get Worse?
- 287 What Can Be Done about Common Eye Symptoms of Graves' Orbitopathy?
- 288 Will the Eyes Go Back to Normal?
- 288 The Changes in My Face Have Affected Me Badly. Can Anything Be Done about Them? Shall I Have My Face Back at the End of Treatment?
- 288 Are There Any Risk Factors for a Progressive and Severe Graves' Orbitopathy?
- 289 Can I Contact Patient Support Groups or Fellow Patients?
- 289 If Graves' Orbitopathy Is an Autoimmune Disease, Does That Mean My Immune System Is Collapsed?
- 290 After Orbital Radiation, When Will It Be Possible to Have a Baby?

291 Atypical Manifestations

Daumerie, C. (Brussels); Fichter, N. (Olten)

- 291 What Are the Atypical Manifestations of Graves' Orbitopathy?
- 291 What Are Other Diseases Mimicking Unilateral or Atypical Graves' Orbitopathy?
- 292 Are the Clinical Presentation and Management of Unilateral Different from Bilateral Graves' Orbitopathy?
- 295 What Is the Prevalence of Unilateral Graves' Orbitopathy?
- 296 Can We Predict the Course of Unilateral Graves' Orbitopathy?
- 297 What Is Euthyroid/Hypothyroid Graves' Orbitopathy?
- 297 How Will You Manage Euthyroid/Hypothyroid Graves' Orbitopathy?
- 298 What Is Globe Subluxation?
- 298 Can Graves' Orbitopathy Patients without Muscle Swelling Be at Risk for Loss of Vision due to Optic Neuropathy?
- 299 References

301 Childhood Graves' Orbitopathy

Bartalena, L. (Varese)

- 301 How Frequent Is Graves' Orbitopathy in Children?
- 302 Are Signs and Symptoms of Graves' Orbitopathy in Childhood Similar to Those in Adulthood?
- 304 Why Is Graves' Orbitopathy in Children and Adolescents Milder than in Adults?
- 305 What Medical Treatment for Graves' Orbitopathy in Children and Adolescents?
- 305 What Modality of Treatment for Hyperthyroidism in Children/Adolescents with Graves' Orbitopathy?
- 306 What about Orbital Decompression in Childhood?
- 306 References

309 Comorbidity in Graves' Orbitopathy

Žarković, M., Knežević, M. (Belgrade)

- 309 What Is the Risk of Diabetes Mellitus in Graves' Orbitopathy?
- 311 What Is the Risk of Osteoporosis in Graves' Orbitopathy?
- 312 What Is the Risk of Mental Disorders in Graves' Orbitopathy?
- 313 What Is the Risk of Dry Eye Syndrome in Graves' Orbitopathy?
- 316 What Is the Risk of Glaucoma in Graves' Orbitopathy?
- 317 What Is the Risk of Cataract in Graves' Orbitopathy?
- 318 What Is the Risk of Retinopathy in Graves' Orbitopathy?
- 318 References

322 Prevention

Marcocci, C.; Marinò, M. (Pisa)

- 322 What Is Primary, Secondary, and Tertiary Prevention?
- 322 What Variables Can Be Modified in the Prevention of Graves' Orbitopathy?
- 323 What Can Be Done in Primary and Secondary Prevention of Graves' Orbitopathy?
- 325 What Can Be Done in Tertiary Prevention of Graves' Orbitopathy?
- 327 What Should One Do when Talking to a Graves' Orbitopathy Patient Who Smokes?
- 327 References

330 Protocols of Non-Surgical Therapies

Bartalena, L. (Varese)

- 330 What Is the Protocol for Selenium?
- 330 What Is the Protocol for Intravenous Glucocorticoids?
- 332 What Is the Protocol for Oral Glucocorticoids?
- 333 What Is the Protocol for Orbital Radiotherapy?
- 334 What Is the Protocol for Cyclosporine?
- 335 What Is the Protocol for Rituximab?
- 336 References

338 The Amsterdam Declaration on Graves' Orbitopathy

Perros, P. (Newcastle upon Tyne)

- 338 What Is the Amsterdam Declaration?
- 339 Why Was It Proposed?
- 340 Have the Targets Been Met?
- 340 Appendix 1: The Amsterdam Declaration
- 341 Appendix 2: Signatories of the Amsterdam Declaration
- 343 References

345 Historical Notes on Graves' Disease

Perros, P. (Newcastle upon Tyne)

- 345 Why Bother about History?
- 346 What Is the Earliest Recorded Case of Graves' Disease and Graves' Orbitopathy?
- 347 What Were the Early Theories about Graves' Disease and Graves' Orbitopathy?
- 348 Who Were the Most Important Contributors in Developing Our Understanding and Treatment of Graves' Orbitopathy?
- 348 What Lessons Should Be Learnt from the History of Graves' Disease and Graves' Orbitopathy?
- 349 References

351 Author Index

352 Subject Index

On behalf of EUGOGO,
Wilmar M. Wiersinga, Editor
George J. Kahaly, Co-Editor

 **EUGOGO** Amsterdam and Mainz, June 2017